Thakur Archana, Lum Lawrence G, Mittal Sandeep
Division of Hematology/Oncology, Department of Medicine, University of Virginia Cancer Center, Charlottesville, VA, USA.
Department of Neurosurgery, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
Methods Mol Biol. 2018;1722:117-126. doi: 10.1007/978-1-4939-7553-2_8.
The common strategy for making bispecific antibodies (BsAbs) involves combining the variable domains of the desired monoclonal antibodies (mAbs) into a single bispecific structure. Bispecific immunotherapeutics has generated many different formats of BsAbs including chemical heteroconjugation of two complete molecules or fragments of monoclonal antibodies, quadroma, F(ab), diabodies, tandem diabodies, and single-chain antibodies (scFv). This chapter describes the process of generating activated T cells and arming T cells with heteroconjugated BsAbs to target cancer cells.
制备双特异性抗体（BsAb）的常见策略是将所需单克隆抗体（mAb）的可变结构域组合成单一的双特异性结构。双特异性免疫疗法已产生了多种不同形式的双特异性抗体，包括两个完整单克隆抗体分子或片段的化学异源缀合、四瘤、F(ab)、双抗体、串联双抗体和单链抗体（scFv）。本章描述了激活T细胞并用异源缀合的双特异性抗体武装T细胞以靶向癌细胞的过程。
